P662: PATIENT-REPORTED OUTCOMES FROM A PHASE 3 RANDOMIZED STUDY OF ZANUBRUTINIB VERSUS BENDAMUSTINE PLUS RITUXIMAB (BR) IN PATIENTS WITH TREATMENT-NAÏVE (TN) CLL/SLL
P. Ghia,
G. Barnes,
K. Yang,
C. Tam,
P. Hillmen,
T. Robak,
J. Brown,
B. Kahl,
T. Tian,
A. Szeto,
J. Paik,
M. Shadman
Affiliations
P. Ghia
1 Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy
G. Barnes
2 BeiGene USA, Inc., San Mateo, United States of America
K. Yang
2 BeiGene USA, Inc., San Mateo, United States of America
C. Tam
3 Peter MacCallum Cancer Centre, Melbourne
P. Hillmen
7 St James’s University Hospital, Leeds, United Kingdom
T. Robak
8 Medical University of Lodz, Lodz, Poland
J. Brown
9 Dana-Farber Cancer Institute, Boston
B. Kahl
10 Washington University School of Medicine, St. Louis
T. Tian
2 BeiGene USA, Inc., San Mateo, United States of America
A. Szeto
2 BeiGene USA, Inc., San Mateo, United States of America
J. Paik
2 BeiGene USA, Inc., San Mateo, United States of America
